Myriad Settlements Mark End of an Era: Antoinette Konski on Gene Patents

Antoinette Konski, Partner, IP lawyer, Foley & Lardner LLP

Bio and Contact Info


Listen (5:42) End of monopolies on gene patents

Listen (7:31) Are panels the way to go?

Listen (4:16) How are you advising your clients now?

Listen (6:59) What is at stake with the FDA's move on LDTs?

Listen (2:57) The special challenge of regulating NGS

This past month one of the most successful genetic testing companies, Myriad Genetics, has been settling one gene patent case after another. Also, the FDA has been attempting to regulate some very complicated lab testing. So we figured we better talk to a lawyer about the devil in the details. We’ve chosen Antoinette Konski of the law firm, Foley and Lardner.

Antoinette agrees that the Myriad settlements indicate the end of an era with gene patents. So how is she advising her life science clients in securing IP?

Antoinette is also interested in the regulation of diagnostics. What does she have to say of the FDA’s recent move on LDTs, particularly with regard to next-gen sequencing tests?